Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2003 | 06-2003 | 03-2003 | 12-2002 | 09-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,853 | -5,297 | -3,788 | -11,783 | -8,986 |
| Depreciation Amortization | 905 | 731 | 264 | 953 | 662 |
| Income taxes - deferred | 102 | 102 | 102 | 13 | 31 |
| Other Working Capital | -1,241 | -910 | -238 | -523 | -372 |
| Other Operating Activity | 2,082 | 2,016 | 2,027 | -945 | -1,101 |
| Operating Cash Flow | $-5,005 | $-3,358 | $-1,633 | $-12,285 | $-9,766 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,915 | 4,507 | 7,815 | 3,733 | 3,558 |
| PPE Investments | 366 | 40 | N/A | -1,118 | -1,024 |
| Purchase Of Investment | 300 | 207 | 76 | N/A | -59 |
| Sale Of Investment | N/A | N/A | N/A | -125 | N/A |
| Other Investing Activity | -65 | -64 | -74 | -99 | -101 |
| Investing Cash Flow | $3,516 | $4,690 | $7,817 | $2,391 | $2,374 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 164 | 127 | 21 | 2 | 1 |
| Common Stock Repurchased | -12 | -12 | N/A | -77 | N/A |
| Financing Cash Flow | $152 | $115 | $21 | $-75 | $1 |
| Exchange Rate Effect | -9 | 9 | 4 | -26 | -34 |
| Beginning Cash Position | 13,350 | 13,350 | 13,350 | 23,345 | 23,345 |
| End Cash Position | 12,004 | 14,806 | 19,559 | 13,350 | 15,920 |
| Net Cash Flow | $-1,346 | $1,456 | $6,209 | $-9,995 | $-7,425 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,005 | -3,358 | -1,633 | -12,285 | -9,766 |
| Capital Expenditure | -3 | N/A | N/A | -1,155 | -1,058 |
| Free Cash Flow | -5,008 | -3,358 | -1,633 | -13,440 | -10,824 |